MozillaZine

eWeek Predicts Mozilla will Challenge Internet Explorer

Monday July 28th, 2003

In his latest opinion piece for eWeek, Jim Rapoza tackles a favourite topic of tech columnists recently: are the Browser Wars coming back? Rapoza thinks that they are and says Microsoft's recent decision to only provide enhancements to Internet Explorer via Windows upgrades could leave an opening for alternative browsers. Mozilla, Rapoza argues, is well-placed to take advantage of this opportunity with its up-to-date and innovative technology.


#46 Re: Welcome to free captialism.

by user4321

Wednesday July 30th, 2003 1:05 AM

You are replying to this message

"'Interesting that you use that figure. I wonder where you got it?' Wall Street Journal. If the figure is wrong then I apologize and I take back what I said."

I can't say unequivocally that it's wrong. However, the fact that it is the same number pulled from the study that the pharmaceutical industry sponsors every year piqued my interest. I'll be very interested to see the exact context in which WSJ quoted it (I don't subscribe, but I imagine I can find it).

"$800 million per drug per company. Big difference. I assume the $12 billion is for the entire industry."

The $12 billion dollar number was, I believe, for the top seven companies in 2001. However, keep in mind that number is for a *single year*. The only other times I have seen the $800 million dollar number it was talking about the industry's annual R&D expenditures. Let's assume for a moment, though, that it was the number spent on a single drug by a single company; how many years was that money spent over?

"My economics teacher told me that supermarkets only make a 0.5% profit."

Think about that for a minute. If that were true, a supermarket chain with 100 stores which each did 1 million dollars per year in business would only have $50,000 to disperse to their stockholders or to use for other purposes. If the chain was owned by a single individual, it would barely make them a living.

It also means that a minor uptick in the price of a single key item (and when you're dealing with things like fruits and vegetables where an entire crop can be wiped out by a single day of bad weather, that kind of volatility is part of the landscape) could wipe out several years' profits. Highly unlikely.

"Thank you so much for your courtesy."

I was not trying to be discourteous, I was trying to be frank. The fact is that the pharaceutical industry probably spends at least as much money trying to convince people that their R&D costs justify their exhorbitant pricing as they do on R&D itself. My point was that unfortunately, that tactic appears to be highly successful.